Genmab A/S (GMAB) Stock Price, News & Analysis

Company Overview

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Key Stats

• Today's Range: $22.07 to $22.36
• 50-Day Range: $18.69 to $22.44
• 52-Week Range: $18.64 to $31.88
• Volume: 719,542 shs
• Average Volume: 1.56 million shs
• Market Capitalization: $14.77 billion
• P/E Ratio: 12.84
• Dividend Yield: N/A
• Price Target: $42.17
• Consensus Rating: Moderate Buy

Genmab A/S Stock Analysis - MarketRank™

Genmab A/S scored higher than 93% of companies evaluated by MarketBeat, and ranked 70th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Genmab A/S has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 7 buy ratings, 4 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Genmab A/S has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 22.76%

Earnings Growth

Earnings for Genmab A/S are expected to grow by 22.76% in the coming year, from $1.45 to $1.78 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Genmab A/S is 12.76, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 23.35.

Price to Earnings Ratio vs. Sector

The P/E ratio of Genmab A/S is 12.76, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 25.93.

Price to Earnings Growth Ratio

Genmab A/S has a PEG Ratio of 2.59. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Genmab A/S has a P/B Ratio of 2.76. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.26% of the float of Genmab A/S has been sold short.

Short Interest Ratio / Days to Cover

Genmab A/S has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Genmab A/S has recently decreased by 6.36%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Genmab A/S does not currently pay a dividend.

Dividend Growth

Genmab A/S does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.26% of the float of Genmab A/S has been sold short.

Short Interest Ratio / Days to Cover

Genmab A/S has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Genmab A/S has recently decreased by 6.36%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.9 / 5
• News Sentiment: 1.03

News Sentiment

Genmab A/S has a news sentiment score of 1.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 18 news articles for Genmab A/S this week, compared to 5 articles on an average week.

Search Interest

8 people have searched for GMAB on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

8 people have added Genmab A/S to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Genmab A/S insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.54% of the stock of Genmab A/S is held by insiders.

Percentage Held by Institutions

Only 7.07% of the stock of Genmab A/S is held by institutions.

GMAB Stock Analysis - Frequently Asked Questions

How have GMAB shares performed this year?

Genmab A/S's stock was trading at $20.87 at the start of the year. Since then, GMAB stock has increased by 6.2% and is now trading at $22.1550.
View the best growth stocks for 2025 here.

How were Genmab A/S's earnings last quarter?

Genmab A/S (NASDAQ:GMAB) released its earnings results on Wednesday, February, 12th. The company reported $0.57 EPS for the quarter, topping analysts' consensus estimates of $0.28 by $0.29. Genmab A/S had a trailing twelve-month return on equity of 16.78% and a net margin of 36.30%.

When did Genmab A/S IPO?

Genmab A/S (GMAB) raised $503 million in an initial public offering on Thursday, July 18th 2019. The company issued 27,800,000 shares at $18.11 per share. BofA Merrill Lynch, Morgan Stanley and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and RBC Capital Markets were co-managers.

Who are Genmab A/S's major shareholders?

Top institutional investors of Genmab A/S include Alliancebernstein L.P. (2.26%), Capital International Investors (0.39%), Deep Track Capital LP (0.30%) and Renaissance Technologies LLC (0.29%).

How do I buy shares of Genmab A/S?

Shares of GMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Genmab A/S own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Genmab A/S investors own include NVIDIA (NVDA), Medtronic (MDT), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Meta Platforms (META), Tesla (TSLA) and Datadog (DDOG).

Company Calendar

• Last Earnings: 2/12/2025
• Today: 2/21/2025
• Next Earnings (Estimated): 5/08/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GMAB
• CUSIP: N/A
• CIK: 1434265
• Web: www.genmab.com
• Phone: (457) 020-2728
• Fax: N/A
• Employees: 2,204
• Year Founded: 1999

Price Target and Rating

• Average Stock Price Target: $42.17
• High Stock Price Target: $50.00
• Low Stock Price Target: $27.00
• Potential Upside/Downside: +87.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 12 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $1.74
• Trailing P/E Ratio: 12.90
• Forward P/E Ratio: 15.48
• P/E Growth: 2.57
• Net Income: $1.14 billion
• Net Margins: 36.30%
• Pretax Margin: 42.57%
• Return on Equity: 16.78%
• Return on Assets: 13.79%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.25
• Quick Ratio: 5.24

Sales & Book Value

• Annual Sales: $3.12 billion
• Price / Sales: 4.76
• Cash Flow: $1.56 per share
• Price / Cash Flow: 14.36
• Book Value: $8.04 per share
• Price / Book: 2.79

Miscellaneous

• Outstanding Shares: 661,770,000
• Free Float: 651,577,000
• Market Cap: $14.85 billion
• Optionable: Optionable
• Beta: 0.96